sales@contrivedatuminsights.com
CDI - Contrive Datum Insights
Press ReleaseMedical Devices

Klebsiella Testing Market Forecast to USD 731 million by 2034, Growing 11.68% a Year

Other is the fastest-growing line at 15.71%; North America is the largest region at 38% of 2025 revenue.

PUNE, INDIA — 20 AUGUST 2026CONTRIVE DATUM INSIGHTS

From USD 270 million in 2025 to USD 731 million in 2034, a 11.68% compound annual rate.

38% of 2025 revenue (USD 102.6 million) is generated in North America.

Other is the fastest-growing line at 15.71% annually.

78% of 2025 revenue sits in Laboratory Test, the largest type line.

The global klebsiella testing market was valued at USD 270 million in 2025. The market is projected to grow from USD 302 million in 2026 to USD 731 million by 2034, exhibiting a compound annual growth rate of 11.68% during the forecast period. Contrive Datum Insights presents this information in its report titled "Klebsiella Testing Market Size, Share & Industry Analysis, By Type (Laboratory Test, Imaging Test, Other), Application (Laboratory Test, Imaging Test, Other), Technology (Culture-Based Testing, Molecular Diagnostics, Immunoassay-Based Testing, MALDI-TOF Mass Spectrometry, Other), End user (Hospital Laboratories, Diagnostic & Reference Laboratories, Academic & Research Institutes, Other), Sample type (Respiratory, Blood, Urine, Other), and Regional Forecast, 2026-2034".

Klebsiella testing refers to the diagnostic products and services used to detect and characterize Klebsiella pneumoniae and related Klebsiella species in clinical and research specimens, spanning laboratory-based culture and biochemical identification, molecular and immunoassay-based detection, and complementary imaging used to support a clinical diagnosis. These tests are used across hospital and reference laboratories, diagnostic testing centers, and academic and research institutes to confirm infection, guide antibiotic selection, and track antimicrobial resistance. Buyers include laboratory directors, hospital procurement teams, and public health agencies responsible for infection surveillance and stewardship programs.

Rising incidence of antimicrobial-resistant Klebsiella infections driving routine resistance testing

Rising incidence of antimicrobial-resistant Klebsiella infections driving routine resistance testing is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 11.68% a year, the type lines exposed to it move fastest: Other compounds at 15.71%, taking its share of revenue from 13% to 18% and its value from USD 35.1 million to USD 131.58 million.

On the upside, the study's bull case assumes faster-than-expected rollout of molecular diagnostics and point-of-care testing across hospital laboratories, combined with accelerated public health funding for antimicrobial resistance surveillance, lifts testing volumes above the base case, which would take 2034 revenue to USD 818.72 million rather than the USD 731 million base case.

However, slower adoption of advanced testing platforms because of budget constraints in public health laboratories, combined with continued reliance on lower-cost culture-based methods, holds testing volumes below the base case, which would hold 2034 revenue to USD 657.9 million. Laboratory Test, which carries 78% of 2025 revenue, already grows at only 11.03% against the market's 11.68%, so the largest part of the base is also its slowest.

Key Players Compete on Laboratory Test Volume and Other Growth

Competition in the global klebsiella testing market runs along the type axis rather than the regional one. Laboratory Test holds 78% of 2025 revenue at USD 210.6 million and remains the largest line through 2034 at 74%, making it the position hardest for a challenger to take. Other, growing at 15.71%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 270 million.

Further Report Findings

SegmentLed 2025 byShare & valueFastest-growing
TypeLaboratory Test78% · USD 210.6 million
ApplicationLaboratory Test78% · USD 210.6 millionOther 15.81%
TechnologyCulture-Based Testing42% · USD 113.4 millionMolecular Diagnostics 14.87%
End userHospital Laboratories46% · USD 124.2 millionAcademic & Research Institutes 12.56%
Sample typeRespiratory38% · USD 102.6 millionOther 12.89%
  • Based on regional analysis, North America led the global klebsiella testing market in 2025 with 38% of global revenue at USD 102.6 million, reaching USD 248.54 million by 2034.
  • Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 30% in 2034, with revenue growing from USD 64.8 million to USD 219.3 million.
  • Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 5.5% by 2034.
  • Other is projected to grow at 15.71% over the forecast period, the fastest of any type line.
  • The United States is the largest single country market at USD 87.21 million in 2025, 32.3% of global revenue.

The report segments the market across five axes; by type, and by application, technology, end user and sample type; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 657.9 million and USD 818.72 million by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.

Regions Covered
North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa
About Contrive Datum Insights

Contrive Datum Insights is a global market intelligence and consulting firm working across investment, information technology, healthcare and manufacturing markets. Every market we publish is sized twice — once top-down from the leading players and once bottom-up from the addressable base — and validated by primary interview. More about CDI.

Asia Pacific
Kunjir Shyama Prestine, Sr. no. 174/1
Jagtap Diary Road, Pimple Saudagar
Pune 411017, India
+91 983 481 6757
United States
21C2 Lakeshore Dr.
Farmington, CT 06032
United States
+1 215 297 4078